Amgen, Inc. reported the first set of results for Lumakras (sotorasib) in combination with another drug – the company’s own EGFR inhibitor Vectibix (panitumumab) – which showed that pairing the KRAS G12C inhibitor with another therapy can significantly boost efficacy in patients with poor prognoses.
First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Phase III Study Being Initiated For Two-Drug Regimen
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
